Statistics for Pembrolizumab in Combination with Ipilimumab as Second-Line or Later Therapy for Advanced Non–Small-Cell Lung Cancer: KEYNOTE-021 Cohorts D and H
Total visits
| views | |
|---|---|
| Pembrolizumab in Combination with Ipilimumab as Second-Line or Later Therapy for Advanced Non–Small-Cell Lung Cancer: KEYNOTE-021 Cohorts D and H | 216 |
Total visits per month
| views | |
|---|---|
| May 2024 | 2 |
| June 2024 | 8 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
File Visits
| views | |
|---|---|
| Gubens_2019_pembrolizumab.pdf | 1280 |
Top country views
| views | |
|---|---|
| United States | 148 |
| China | 14 |
| Germany | 8 |
| Ukraine | 7 |
| United Kingdom | 5 |
| Sweden | 5 |
| Canada | 3 |
| Greece | 3 |
| Japan | 3 |
| Russia | 2 |
| Bangladesh | 1 |
| France | 1 |
| Ireland | 1 |
| India | 1 |
| Malaysia | 1 |
| Portugal | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 51 |
| Fairfield | 22 |
| White Plains | 9 |
| Cambridge | 8 |
| Kiev | 7 |
| Houston | 6 |
| Jacksonville | 6 |
| Kiez | 5 |
| Stockholm | 4 |
| Beijing | 3 |
| Birmingham | 3 |
| Heraklion | 3 |
| San Francisco | 3 |
| Toronto | 3 |
| Wuhan | 3 |
| Brooklyn | 2 |
| New York | 2 |
| Ann Arbor | 1 |
| Augsburg | 1 |
| Bellevue | 1 |
| Berlin | 1 |
| Chengdu | 1 |
| Delhi | 1 |
| Dublin | 1 |
| Duncan | 1 |
| Gifu | 1 |
| Guangzhou | 1 |
| Hollywood | 1 |
| Indianapolis | 1 |
| Linda-a-velha | 1 |
| Moscow | 1 |
| Motala | 1 |
| Paris | 1 |
| Philadelphia | 1 |
| Rosedale | 1 |
| Saint Petersburg | 1 |
| Seagrove | 1 |
| Seremban | 1 |
| Shenyang | 1 |
| Siping | 1 |
| Tianjin | 1 |
| Valley Stream | 1 |